Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Oncology Market Trends GLP-1 Drugs Clinical Research Obesity Treatment Market Competition Regulatory Approval Generic Drugs

FDA Approves Corcept’s Lifyorli for Platinum-Resistant Ovarian Cancer

The decision adds a new option in a hard-to-treat cancer with modest survival gains.

UCB Picks Georgia’s Rowen for $2 Billion Biologics Campus

AbbVie and Bristol Myers Defy Their Sector With Rising Dividends Fueled by New Drugs

Eton Pharma Launches FDA-Approved Desmota as Revenue and Margins Jump

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

Zevra Sells SDX Portfolio to Commave for $50 Million, Settles Delaware Suit

Injectable Peptides Surge in Popularity as Regulators Sound Safety Alarms

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Invesco Small Cap Value Fund Beats Benchmark in Q4 as AI Plays Shape Portfolio

Can-Fite's Namodenoson Clears Phase IIa Safety Bar in Pancreatic Cancer

Collegium Reports Record 2025 Results, Projects Strong 2026 for Jornay as Hikma Generic Nears

CHMP Backs Xolremdi for WHIM Syndrome Under Exceptional Circumstances

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

Ironwood Sees LINZESS Above $1.1 Billion in 2026 as FDA-Aligned STARS II Nears Launch

Geron Guides 2026 Rytelo Sales to $220–$240 Million After $184 Million Debut Year

AbbVie to Invest $380 Million in Two North Chicago API Plants

Bayer Sues J&J Over Erleada Marketing, Alleging False Superiority Claims Versus Nubeqa